#### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

## 1.-36. (Canceled)

- 37. (Currently Amended) A composition for detecting a <u>breast</u> cancer cell in a biological sample of a patient, said composition comprising:
  - (a) a first oligonucleotide; and
  - (b) a second oligonucleotide;

wherein said first oligonucleotide and said second oligonucleotide hybridize to a first polynucleotide, or the complement thereof, and to a second polynucleotide, or the complement thereof, respectively; wherein said first polynucleotide and said second polynucleotide are selected from the group consisting of the polynucleotides depicted in SEQ ID NO: 75 and SEQ ID NO: 7. first polynucleotide is unrelated in nucleotide sequence from said second polynucleotide; and wherein said first polynucleotide and said second polynucleotide are tissue-specific polynucleotides of the cancer cell to be detected.

### 38.-39. (Canceled)

- 40. (Currently Amended) The composition of any one of claim 37—and elaim 38 wherein said oligonucleotides are selected from the group consisting of oligonucleotides as disclosed in SEQ ID NO: 58 and 55.
- 41. (Currently Amended) A composition for detecting a <u>breast</u> cancer cell in a biological sample of a patient, said composition comprising:
  - (a) a first oligonucleotide pair; and

# (b) a second oligonucleotide pair;

wherein said first oligonucleotide pair and said second oligonucleotide pair hybridize to a first polynucleotide—(, or the complement thereof)—, and to a second polynucleotide (, or the complement thereof), respectively; wherein said first polynucleotide and said second polynucleotide are selected from the group consisting of the polynucleotides depicted in SEQ ID NO: 75 and SEQ ID NO: 7 polynucleotide is unrelated in nucleotide sequence from said second polynucleotide; and wherein said first polynucleotide and said second polynucleotide are tissue-specific polynucleotides of the cancer cell to be detected.

#### 42.-43. (Canceled)

- 44. (Previously Presented) The composition of any one of claim 41—and claim 42 wherein said oligonucleotides are selected from the group consisting of oligonucleotides as disclosed in SEQ ID NOs: 53, 54, 56, and 57.
- 45. (Previously Presented) A composition comprising an oligonucleotide primer or probe of between 15 and 100 nucleotides that comprises an oligonucleotide selected from the group consisting of oligonucleotides depicted in SEQ ID NOs: 53-58.
- 46. (Currently Amended) The composition of claim 45 eomprising anwherein the oligonucleotide primer or probe is selected from the group consisting of oligonucleotides depicted in SEQ ID NOs: 53-58.